Good morning, Marco. Two things moved yesterday that are worth your five minutes. WHO's emergency
committee met and kept the DRC Ebola outbreak at global-emergency status — it has now passed 5,000
cases and become the deadliest in that country's history, driven by a strain with no licensed
vaccine. And the FDA opened a public docket on how to regulate generative-AI medical devices,
which is the other half of the story you read here yesterday about two-thirds of hospitalists
using AI and a third being trained on it. Plus a rounding-structure piece that describes what your
nights already look like, and Tatis Jr. taking a grand slam away from Lindor. Coffee, then sleep.
Section A — Top Stories
Update: DRC Ebola passes 5,000 cases, becomes the country's deadliest outbreak — WHO keeps the global emergency in place
What's new
WHO's emergency committee met Tuesday and reaffirmed the Democratic Republic of the Congo
outbreak as a public health emergency of international concern. Confirmed cases have crossed
5,000 and deaths exceed 2,320, which passes the 2018–2020
outbreak's 2,299 and makes this the deadliest in the DRC's history — its seventeenth. Tedros
told the meeting the epidemic is spreading at "unprecedented speed" and is "far from being
under control," with transmission chains still unidentified. The outbreak was declared May 17,
but sequencing shows it began circulating in February. It has reached a sixth
province
(Al Jazeera / AFP / Reuters,
WHO situation page).
Why it matters to you
The clinically important detail is the strain: this is Bundibugyo, for which
there is no approved vaccine and no approved therapeutic. The Ervebo/rVSV vaccine and the
monoclonal antibodies that shortened the 2018–2020 outbreak are Zaire-strain products and do
not apply here. An Oxford-developed candidate dosed its first volunteer in the UK last month,
with doses manufactured in India and staged for use if trials read out. Practically, that turns
this into a screening and isolation problem rather than a treatment one. Your exposure
is low but non-zero: Southwest Florida moves international travelers, and the presentation that
matters — fever, myalgias, GI symptoms in someone back from Central or East Africa in the last
21 days — is exactly the undifferentiated picture that lands on a night admission and gets
anchored to gastroenteritis or malaria.
Action
Worth confirming, once, that your ED triage and admission templates still prompt a travel
history with a 21-day window and a named country list, and that you know who the on-call
contact is for a viral hemorrhagic fever pathway at 3 a.m. Most hospitals wrote that policy in
2014 and haven't opened it since. Two-minute answer, and you'd rather not be looking for it
while the patient is in the hallway.
FDA opens the docket on generative-AI medical devices — and clinicians are explicitly invited
What happened
FDA released a discussion paper yesterday on how it might regulate generative-AI-enabled
medical devices, covering risk assessment, premarket evaluation, post-market monitoring,
foundation models and agentic systems. The proposal sketches a two-axis risk framework and a
premarket approach built on competency assessment — non-clinical benchmarking
followed by clinical confirmation, rather than a single locked-algorithm clearance. Comments
are due Oct. 19 under docket FDA-2026-N-7874, and the agency says it wants
input from clinicians and the public, not only manufacturers
(FDA,
AHA,
docket).
Why it matters to you
This is the regulatory half of the number in yesterday's report: SHM found 64% of hospitalists
using AI clinically and about a third trained on it, with decision support the most common use.
January's revised clinical-decision-support guidance moved a large class of single-recommendation
tools out of premarket review on the theory that a clinician reviews and finalizes the output —
which means the review step is now the safety control, and the reviewer is you. Whatever
framework comes out of this docket will decide whether that stays true for generative tools that
draft assessments and summarize charts, or whether the agency asks for benchmarked performance
before deployment. Nights is the shift where the "a clinician will catch it" assumption is
thinnest.
Action
If any part of this year annoys you — an AI-generated summary that dropped a code status, a
decision-support suggestion nobody could trace — the docket is open until October and comments
from practicing clinicians are rare enough to get read. Ten minutes, no institutional sign-off
needed.
Split rounding teams get a serious look — and the model is basically your job description
What happened
A piece out yesterday walks through hospitals separating the admitting function from
the rounding function instead of asking one team to do both. At Mount Sinai, physician
assistants staff a dedicated admitting team by day and nocturnists fill that role overnight.
Andrew Dunn, MD, chief of hospital medicine for Mount Sinai Health System, makes the efficiency
case — "everyone gets to focus on their primary task." Christopher Migliore, MD, at Columbia
University Irving Medical Center prefers mixed teams, arguing the split costs continuity
(Medscape).
Why it matters to you
Nocturnists have run the split model for years without anyone calling it that — you admit, you
don't round, and the continuity cost gets paid at handoff. What's changing is that day teams are
now adopting it deliberately, which shifts where the seams are. If a daytime admitting team owns
the front door until 7 p.m., your admissions arrive later and denser; if a rounding team owns
the list, the person receiving your handoff has less context on the patients you admitted than
the resident who used to do both. The continuity argument Migliore makes is the one worth
tracking, because in a split system it lands almost entirely on the quality of the written
handoff.
Action
Decent group-meeting item if your service is considering a daytime admitter: ask what happens to
the night-to-day handoff structure, since that's the interface that absorbs the change.
An outbreak that had a three-month head start, a comment box that's open until October, and a
grand slam that never made it out of the park. Sleep well, Marco.